Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Clinical trial NCT04185220 · COMPLETED
Trial details
- NCT number
- NCT04185220
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-26
- Primary completion
- 2020-11-06
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.